Journal
TUMOR BIOLOGY
Volume 30, Issue 4, Pages 221-231Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1159/000240634
Keywords
Antibody; Molecular evolution; MUC1; Phage display; Specificity fine-tuning
Categories
Funding
- BioInvent International
- Swedish Research Council
- Swedish Cancer Foundation
- M. Bergvall Foundation
- Assar Gabrielsson Foundation
- Jubileumsklinikens Research Foundation
- European Union [QLK3-CT-199-00217, QLK3-CT-2002-02010]
Ask authors/readers for more resources
The MUC1 mucin is differentially expressed and glycosylated in cancer tissue as opposed to healthy tissue. Due to these differences, MUC1 is considered a potential biomarker suitable for cancer diagnosis and therapy. In a previous study, the human MUC1-specific antibody 12ESC-6 was able to bind a sequence variant of the tandem repeat of MUC1 that is not recognized by many other MUC1-specific antibodies. It was also found to bind efficiently to MUC1-carrying cells. We have now used 12ESC-6 as starting point for random mutagenesis to isolate variants with improved ability to bind MUC1 in human tumor tissue. The resulting 12ESC-6 variants were shown to recognize not only the naked MUC1 tandem repeat but even more so glycosylated variants thereof, in particular those carrying the GalNAc (Tn) glycoform. Selected variants of 12ESC-6 demonstrated improved staining of MUC1 on cell lines using flow cytometry and improved staining of the antigen in breast tumor tissue by immunohistochemistry. Molecular evolution and specific fine-tuning thus have the potential to improve the performance of antibody specificities targeting tumor-associated epitopes on MUC1 mucin. Copyright (C) 2009 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available